{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:43:07Z","timestamp":1792593787280,"version":"4.5.0"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Thromboembolic events (TEEs) are a rare, but serious adverse event for patients receiving immunoglobulin therapy. Patient and product-specific risk factors can increase the risk for these adverse events. To reduce this risk, ADMA has further optimized the manufacturing process of intravenous immunoglobulin (IVIG) products to remove impurities that may precipitate these events. Key attributes were tested in three lots of ADMA's IVIG products from the further optimized process. Across the three lots analyzed, quantification values for each parameter tested were at or below the limit. Since the commercial release of ADMA's IVIG products produced using the further optimized manufacturing process, ADMA's post-marketing pharmacovigilance surveillance and the FDA Adverse Event Reporting System has received zero reported cases of TEEs from July 1, 2025 to July 31, 2026. ADMA's further optimized manufacturing process ensures removal of impurities while also ensuring high recovery of immunoglobulin from source material.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1874074","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:06:06Z","timestamp":1790247966000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Further optimization of an ADMA Biologics' proprietary manufacturing process to ensure removal of impurities associated with thrombosis risk in IVIG products"],"prefix":"10.3389","volume":"13","author":[{"given":"Kaitlin","family":"Kestenberg","sequence":"first","affiliation":[{"name":"ADMA Biologics","place":["Boca Raton, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Holler","sequence":"additional","affiliation":[{"name":"ADMA Biologics","place":["Boca Raton, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"O\u2019Grady","sequence":"additional","affiliation":[{"name":"ADMA Biologics","place":["Boca Raton, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Avila","sequence":"additional","affiliation":[{"name":"ADMA Biologics","place":["Boca Raton, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Capra","sequence":"additional","affiliation":[{"name":"ADMA Biologics","place":["Boca Raton, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Grossman","sequence":"additional","affiliation":[{"name":"ADMA Biologics","place":["Boca Raton, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1111\/j.1537-2995.2012.03589.x","article-title":"Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010","volume":"52","author":"Daniel","year":"2012","journal-title":"Transfusion"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"key":"B3","volume-title":"ASCENIV (immune Globulin Intravenous, Human-slra) 10% Liquid [package Insert]","year":"2019"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2217\/imt-2019-0157","article-title":"Manufacturing process optimization of ADMA Biologics\u2019 intravenous immunoglobulin products, BIVIGAM\u00ae and ASCENIV\u2122","volume":"11","author":"Wasserman","year":"2019","journal-title":"Immunotherapy"},{"key":"B5","first-page":"WMC002002","article-title":"Identification of activated FXI as the major biochemical root cause in IVIG batches associated with thromboembolic events. Analytical and experimental approaches resulting in corrective and preventative measures implemented into the octagam manufacturing process","volume":"2","author":"Roemisch","year":"2011","journal-title":"WebmedCentral Immunother"},{"key":"B6","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/ajh.24358","article-title":"Intravenous immune globulin and thromboembolic adverse events: a systematic review and meta-analysis of RCTs","volume":"91","author":"Ammann","year":"2016","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/jama.2013.15267","article-title":"FDA: thrombosis risk with immune globulin products","volume":"310","author":"Mitka","year":"2013","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1253177","DOI":"10.3389\/fcvm.2023.1253177","article-title":"Cation exchange chromatography removes FXIa from a 10% intravenous immunoglobulin preparation","volume":"10","author":"Kang","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B9","volume-title":"BIVIGAM (immune Globulin Intravenous, Human) 10% Liquid [package Insert]","year":"2012"},{"key":"B10","year":"2026"},{"key":"B11","year":"2025"},{"key":"B12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/vox.12025","article-title":"Thromboembolic events associated with immunoglobulin treatment","volume":"105","author":"Funk","year":"2013","journal-title":"Vox Sang"},{"key":"B13","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jaci.2011.06.047","article-title":"The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature","volume":"129","author":"Rachid","year":"2012","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1874074\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:19:37Z","timestamp":1792592377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1874074\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":13,"alternative-id":["10.3389\/fcvm.2026.1874074"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1874074","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1874074"}}